title: [Errors and hazards in oncology: radiation oncology].
abstract: Adverse effects and hazards which have their origin from radiation using conventional techniques like 3-D conformal radiotherapy and total radiation doses are well known. However little is known about the sprectum of especially late toxicity after radiation using new technologies like intensity modulated radiotherapy (IMRT) combined with novel target volume and dose concepts. Since IMRT allows for selective protection of the large salivary glands this technique improves the intermediate term quality of life and is the standard of care despite many details need further prospective evaluation. Combining cytotoxic drugs and radiotherapy yield improved survival in well-defined high risk patients. However morbidity and mortality of these protocols are high and deserve special expertise and supportive therapy. EGF-receptor antibodies have gained well defined indications, albeit specific toxicities in combination with irradiation deserve prospective studies and special attention.
authors.affiliation: Klinik für Strahlentherapie und Radioonkologie, Universitätsklinikum Jena, Jena. thomas.wendt@med.uni-jena.de
authors.forename: T G
authors.initials: TG
authors.lastname: Wendt
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects / Q000627:therapeutic use; D000068818:Cetuximab; D004307:Dose-Response Relationship, Radiation; D066246:ErbB Receptors / Q000037:antagonists & inhibitors; D006801:Humans; D009381:Neoplasms, Radiation-Induced / Q000209:etiology* / Q000401:mortality / Q000517:prevention & control; D010039:Otorhinolaryngologic Neoplasms / Q000401:mortality / Q000532:radiotherapy*; D011788:Quality of Life; D011832:Radiation Injuries / Q000209:etiology* / Q000401:mortality / Q000517:prevention & control; D011835:Radiation Protection; D011880:Radiotherapy Planning, Computer-Assisted; D020266:Radiotherapy, Conformal / Q000009:adverse effects; D050397:Radiotherapy, Intensity-Modulated / Q000009:adverse effects; D012469:Salivary Glands / Q000528:radiation effects; D015996:Survival Rate
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D066246:ErbB Receptors; D000068818:Cetuximab